Join
Live feed
·
PRReleasevia Quantisnow
Lunai Bioworks Inc. logo

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

ByQuantisnow·Wall Street's wire, on your screen.
LNAI· Lunai Bioworks Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LNAI (Lunai Bioworks Inc.) and more on Quantisnow.